FATE · Nasdaq · ·
US$2.38+0.4%9月29日 收盘
截至 2026年6月30日 的季度,与去年同季度相比。
| 指标 | 截至该日的 3 个月2026年6月30日 | 截至该日的 3 个月2025年6月30日 | 变动 |
|---|---|---|---|
| 营业收入合计 | US$2.1M | US$1.9M | +9.18% |
| 利润 | -US$30.2M | -US$34.1M | +11.48% |
| 每股收益 | -US$0.25 | -US$0.29 | +13.79% |
| 自由现金流 | -US$23.5M | -US$25.9M | +9.51% |
这些是单季度数字,不是滚动一年——本站其他地方的数字覆盖十二个月,会大得多。季节性业务在两者之间摆动很大:ServiceNow 在十二月季度赚 20 亿美元自由现金流,在六月季度只有 5 亿。
对比对象是去年同一季度,而不是分析师预测。要说“超预期”或“不及预期”需要一致预期数据,那是我们没有的授权数据——而搞错它比不提更糟。
暂无 Fate Therapeutics Inc. 的业绩电话会文字记录。
“Dosing of the first patient in RECLAIM-LN, our Phase 2 potentially registrational trial, is an exciting milestone as we work to address significant unmet medical needs in patients with lupus nephritis using our FT819 off-the-shelf CAR T-cell treatment,”
逐字引自公告,且只在文件将其归于具名人士时才展示。
公告在收盘后或开盘前发布,因此这里的变动是随后的那个交易日。
FT819 is an off-the-shelf CD19-targeting chimeric antigen receptor (CAR) T-cell product candidate engineered to improve safety and efficacy. Analogous to master cell banks used to mass produce biopharmaceutical drug products such as monoclonal antibodies, a precisely engineered clonal master induced pluripotent stem cell (iPSC) bank serves as the starting cell source to manufacture FT819, overcoming numerous limitations associated with patient- and donor-sourced CAR T-cell therapies. FT819 is well-defined and uniform in composition, produced at a low cost of goods, and can be stored in inventory for off-the-shelf, on-demand availability to enable access for a broad patient population. This research was additionally made possible by funding from the California Institute for Regenerative Medicine (CIRM), a state agency in California that supports research in regenerative medicine, stem cell therapy, gene therapy, and clinical trials. (Grant number: CLIN2-16303)
公司自己的描述,取自公告末尾。
引述和公司简介来自 Fate Therapeutics Inc. 于 2026年8月13日 提交的第 2.02 项 8-K 文件;表格根据其季度报告编制。 在 EDGAR 上阅读公告 股价已按拆股和分红复权。